5% Off
Cytogem1 gm/vial
Drug International Ltd.
৳4275.00
Add to cart
Generic medicine
Gemcitabine: Brands, Price & Uses in Bangladesh
Gemcitabine is a cytotoxic chemotherapy agent administered only under the supervision of an oncology specialist as part of a physician-directed cancer treatment protocol.
About Gemcitabine
Indications of Gemcitabine
Gemcitabine is a cytotoxic chemotherapy agent administered only under the supervision of an oncology specialist as part of a physician-directed cancer treatment protocol. Its use is classified by strength of evidence as follows:
Established / FDA-approved indications
- Pancreatic cancer: First-line treatment of locally advanced (non-resectable stage II or stage III) or metastatic adenocarcinoma of the pancreas, including patients previously treated with fluorouracil.
- Non-small cell lung cancer (NSCLC): First-line treatment of inoperable, locally advanced (stage IIIA or IIIB) or metastatic (stage IV) NSCLC, in combination with cisplatin.
- Breast cancer: In combination with paclitaxel, for metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated.
- Ovarian cancer: In combination with carboplatin, for advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy.
Guideline-supported / commonly used off-label indications
- Bladder (urothelial) cancer: In combination with cisplatin, as a guideline-recognised regimen for locally advanced or metastatic urothelial carcinoma, particularly when cisplatin-based standard regimens are not suitable.
- Biliary tract cancer (cholangiocarcinoma/gallbladder cancer): In combination with cisplatin, a guideline-supported regimen for advanced biliary tract cancers.
- Other malignancies such as soft-tissue sarcoma and malignant mesothelioma, used off-label in select cases based on oncologist judgment and institutional protocols.
The exact indication, combination partner, and treatment protocol for Gemcitabine are always determined by the treating oncologist based on cancer type, stage, and patient fitness.
Dosage & Administration of Gemcitabine
Gemcitabine dosing, scheduling, and duration are determined solely by the treating oncologist based on the specific cancer type, combination regimen, body surface area (BSA), and the patient's hematologic and organ function. The information below reflects typical protocol-based regimens and is not intended for self-administration or dose selection by patients.
| Indication | Typical regimen (physician/protocol-determined) |
|---|---|
| Pancreatic cancer (single agent) | Gemcitabine 1000 mg/m² IV over 30 minutes, once weekly, per standard cycle schedules such as weekly x7 followed by a rest week, then weekly x3 with a rest week for subsequent cycles. |
| Non-small cell lung cancer (with cisplatin) | Gemcitabine typically 1000–1250 mg/m² IV on Days 1 and 8 (or Days 1, 8, 15) of a 21- or 28-day cycle in combination with cisplatin, per selected protocol. |
| Breast cancer (with paclitaxel) | Gemcitabine 1250 mg/m² IV on Days 1 and 8 of a 21-day cycle, given after paclitaxel, in combination with paclitaxel. |
| Ovarian cancer (with carboplatin) | Gemcitabine 1000 mg/m² IV on Days 1 and 8 of a 21-day cycle, in combination with carboplatin given on Day 1. |
Administration
- Gemcitabine must be administered only as a slow intravenous infusion by a qualified oncology healthcare professional under close medical supervision; it is never given orally, intramuscularly, or self-administered at home.
- Standard infusion time is approximately 30 minutes; infusion times longer than 60 minutes or more frequent than weekly dosing have been associated with increased toxicity and are not recommended outside specific protocols.
- Doses are calculated by body surface area (BSA, mg/m²) and may be reduced, delayed, or withheld based on absolute neutrophil count, platelet count, and evidence of non-hematologic toxicity, as determined by the treating physician.
- Pre-medication (e.g. antiemetics) and monitoring of complete blood counts before each dose are part of standard protocol.
Renal/hepatic impairment
Gemcitabine should be used with caution and close monitoring in patients with pre-existing renal or hepatic impairment, as clearance may be reduced; specific validated dose-adjustment guidelines are not well established, so dosing in this setting is individualized by the oncologist, often with more frequent monitoring and dose reduction.
Side Effects of Gemcitabine
Side effects of Gemcitabine are common because it is a cytotoxic chemotherapy agent. Serious toxicities are covered fully under Precautions and Warnings; this section lists the overall frequency pattern.
Very common
- Myelosuppression (low white blood cell, platelet, and red blood cell counts) — see Precautions and Warnings
- Nausea and vomiting
- Elevated liver enzymes (transaminases, alkaline phosphatase)
- Flu-like symptoms (fever, chills, headache, myalgia, fatigue), usually within hours of infusion
- Rash and mild itching
- Hair thinning/hair loss (usually mild)
- Mild proteinuria and hematuria
- Peripheral edema
Less common but clinically important
- Diarrhea, stomatitis (mouth sores)
- Injection/infusion site reactions
- Constipation
Rare but serious (see Precautions and Warnings for full detail)
- Severe pulmonary toxicity (interstitial pneumonitis, pulmonary edema, capillary leak syndrome, ARDS)
- Hemolytic uremic syndrome (HUS) / thrombotic microangiopathy
- Severe hepatotoxicity including liver failure
- Posterior reversible encephalopathy syndrome (PRES)
- Severe skin reactions
Contraindications of Gemcitabine
Gemcitabine is contraindicated in patients with a known hypersensitivity to Gemcitabine or to any component of the formulation.
Frequently Asked Questions about Gemcitabine
What is Gemcitabine used for?
Gemcitabine is an intravenous chemotherapy medicine used to treat certain cancers, including pancreatic cancer, non-small cell lung cancer (with cisplatin), breast cancer (with paclitaxel), and ovarian cancer (with carboplatin). It is also used in some other cancers such as bladder and biliary tract cancer as part of a physician-directed treatment plan.
How is Gemcitabine given?
Gemcitabine is given only as a slow intravenous infusion, usually over about 30 minutes, by trained oncology healthcare staff in a hospital or infusion center. It is not a tablet or capsule and cannot be taken at home or self-administered.
What are the most serious side effects of Gemcitabine?
The most serious risks of Gemcitabine include severe bone marrow suppression (low blood counts, raising infection and bleeding risk), lung toxicity (including rare but serious breathing problems), a rare but life-threatening kidney condition called hemolytic uremic syndrome, liver problems, and rare brain-related reactions such as posterior reversible encephalopathy syndrome. Your oncology team will monitor you closely with blood tests and check-ups to watch for these.
Can Gemcitabine be used during pregnancy or breastfeeding?
No. Gemcitabine can harm a developing baby and is not recommended during pregnancy; effective contraception is required during and after treatment, as advised by your oncologist. Breastfeeding should also be stopped during Gemcitabine treatment because it is not known whether the medicine passes into breast milk and could harm a nursing infant.
Will I need blood tests while receiving Gemcitabine?
Yes. Because Gemcitabine commonly lowers white blood cell, platelet, and red blood cell counts, your doctor will check your blood counts before every dose, and will also monitor your kidney and liver function periodically, adjusting or delaying doses as needed for your safety.
What should I do if I think I've had too much Gemcitabine or have severe symptoms after treatment?
Because Gemcitabine is given under direct medical supervision, any concerns about overdose or severe reactions should be reported immediately to your oncology team or emergency medical services; do not attempt to manage severe symptoms at home. There is no specific home antidote — prompt medical evaluation and supportive care are essential.
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.